APLT News and Press, Applied Therapeutics Inc. From 04/29/20

The following slide deck was published by Applied Therapeutics, Inc. in conjunction with this Read more ...

The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...

AT-007 demonstrated rapid and sustained reduction in toxic galactitol levels with no accompanying increase in galactose Positive trend on MRI outcomes, including indirect measures of edema, neuronal health and brain galactitol levels in AT-007-treated patients 40 mg/kg dose of AT-00...

FDA signs off on Emergency Use Authorization for Humanigen's ( OTCQB:HGEN ) lenzilumab for compassionate use for preventing and treating cytokine storm in severely ill COVID-19 patients. More news on: Humanigen, Inc., Applied Therapeutics, Inc., Humana Inc., Healthcare stocks news, Stock...

New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients Hospitals in New York City have commenced investigator-initiated studies; additional programs expected NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (...

Today, we will see why March 2020 can be a good entry point for Applied Therapeutics ( APLT ). Company overview Founded in 2016 and headquartered in New York, Applied Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel drug candidates against va...

Applied Therapeutics (NASDAQ: APLT ): FY GAAP EPS of -$3.55 misses by $0.59 . Cash and cash equivalents and short-term investments of $38.9M Press Release More news on: Applied Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results f...

NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will ...

The investment research arm of Barclays (NYSE: BCS ,LSE:BARC) is not worried about drug pricing concerns in the US; instead, it has a positive outlook for the country’s biopharma industry. On Wednesday (February 26), Barclays Capital launched its coverage of the US biopharma space w...